Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of HNC364 IM vs Rasagiline Oral in Healthy Adults
NCT06798519Phase 1Active, not recruiting
- Sponsor
- Guangzhou Henovcom Bioscience Co., Ltd.
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of HNC364 in Parkinson's disease (PD) (2 arms), sponsored by Guangzhou Henovcom Bioscience Co., Ltd. Primary endpoints: Area under the concentration-time curve from time 0 to dose interval and Number of Participants With Treatment Emergent Adverse Events. Started May 2026; status: active, not recruiting.
02
Drugs
HNC364
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06798519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798519.